CD4 and myeloid sarcoma: CD4+NKG2D+ T cells from MS patients expressed even higher levels of markers for migration, activation, and cytolytic effector molecules and produced higher levels of IFN-γ and IL-17 upon stimulation in comparison to CD4+NKG2D+ T cells from healthy donors.